Navigation Links
EpiCept Reports Regulatory Progress on Ceplene(TM)
Date:9/17/2007

ong term after relapse. There are currently no proven treatments for maintaining long-term remission for AML patients.

About EpiCept Corporation

EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept has a staged portfolio of pharmaceutical product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in Tarrytown, N.Y., and its research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.

Forward-Looking Statements

This news release and any oral statements made with respect to the information contained in this news release, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on EpiCept's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU or that Ceplene, if approved, will not achieve significant commercial success, the risk that Myriad's development of Azixa(TM)* will not be successful, the risk that Azixa will not receive regulatory approval or achieve significant commercial success, the risk that we will not receive any significant payments under our agreement with Myriad, the risk
'/>"/>

SOURCE EpiCept Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
2. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... FRANCISCO, Calif. , Aug. 3, 2015 /PRNewswire/ ... the treatment of cancer, today announced the promotion ... Debanjan Ray , who previously served ... management, has been promoted to senior vice president ... CytomX, Mr. Ray held positions as the vice ...
(Date:8/3/2015)... OSAKA, Japan and FLORHAM PARK, ... today announced that once-daily naldemedine met its primary and ... for the treatment of opioid-induced constipation (OIC) in adult ... oral, peripherally acting mu-opioid receptor antagonist (PAMORA). This is ... its primary and key secondary endpoints. Study ...
(Date:8/3/2015)... Inc. (PK:ECIA), a medical device company owning patented surgical ... invasive surgery, today announced financial results for its fiscal ... The Company posted quarterly net revenue of $2.454 ... or $(0.02) per share. These results compare to net ... $202 thousand, or $(0.02) per share, in the year-ago ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... , ST. LOUIS , Feb. 8 ... its first Stereotaxis Magnetic Navigation System in Taiwan at ... a Grand Opening event on January 26 that received ... been successfully performed using Stereotaxis at the hospital. , "All too ...
... Md. , Feb. 8 Novavax, Inc. (Nasdaq: ... to discontinue negotiations in its pursuit of the previously announced ... Novavax,s virus-like-particle (VLP)-based vaccines against influenza in the country of ... inability to agree on acceptable terms of the proposed collaboration ...
Cached Medicine Technology:Stereotaxis Installs First System in Taiwan 2Stereotaxis Installs First System in Taiwan 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 2Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 3Novavax Terminates Negotiations with ROVI Pharmaceuticals for Influenza Vaccine Collaboration 4
(Date:8/3/2015)... ... ... Dental practice in Los Angeles , Sunset Plaza Dental, is now ... health emergencies, such as broken arms or a heart attack, should be evaluated in ... during a dental emergency. This is important, because dental trauma is extremely common. More ...
(Date:8/3/2015)... ... 03, 2015 , ... The art of preparing and cooking food comes naturally ... a young age, Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that ... from My Persian Kitchen with the world. , Since Americans tend to be undereducated ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... “Designing Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has ... with access to the tactics, techniques and practices required to design and develop ...
(Date:8/3/2015)... ... 03, 2015 , ... A July 9 article from USA Today ... according to the American Dental Association. According to a study by the American Dental ... million in a single year to 2.2 million a year. Dentists and ADA officials ...
(Date:8/3/2015)... Decatur, Illinois (PRWEB) , ... August 03, 2015 , ... ... (IBAM NA) effective July 31. , The acquisition includes all of IBAM NA’s ... the opportunity to have both, a robust regionally located business, as well as a ...
Breaking Medicine News(10 mins):Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2
... RED BANK, New Jersey, BRUSSELS and MELBOURNE, January 30, ... over a century of expertise, the global leader in ... the web. The,new http://www.ansell.com website is now ... new Investor Centre. , The ...
... AHA says research looked at smoking bans, acute care, ... (HealthDay News) -- Studies on smoking bans, acute care ... childhood obesity were among the top 10 major advances ... to the American Heart Association. , "It,s always difficult ...
... sugary fare may be to blame, researchers say , , ... TV more than five hours a day are prone ... suggests. , The connection? Too much time spent watching ... food choices, University of Minnesota researchers say. , "Television ...
... the nation,s first and largest provider of outsourced medical ... announced today that it has appointed Carmen Fontanez to ... Payor Sales and Services. In her new role, ... operations that serve hundreds of health plans across the ...
... German . , More than half of ... agents, are glycoproteins, which means that they contain sugar ... homogeneous sugar component. With modern purification techniques, it is ... for systematic biomedical studies. Synthesis in the lab is ...
... LISLE, Ill., Jan. 30 SpineMark Corporation,a spinal ... to develop Spine Centers of Excellence, has entered ... quality spinal care at,cost effective rates through the ... solution, the Healthplace Surgery Benefit(TM). As a ...
Cached Medicine News:Health News:Ansell Limited Launching a New Global Website 2Health News:Top 10 Heart-Stroke Advances for 2008 2Health News:Top 10 Heart-Stroke Advances for 2008 3Health News:Adult Fast-Food Diets Tied to Too Much TV as Teen 2Health News:Adult Fast-Food Diets Tied to Too Much TV as Teen 3Health News:Access MediQuip Appoints Executive Vice President of Payor Sales and Services 2Health News:Enzyme with a sugar antenna 2Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 2Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 3Health News:SpineMark Partners With Healthplace America to Offer Access to Top Quality Spinal Care 4
The Protract stem offers a press-fit option which will allow choice of standard or lateralized neck offsets while keeping a consistent leg length....
Performa cemented stem....
Porous foundation 480 series....
Porous foundation 440 series....
Medicine Products: